US House ban on pay-for-delay settlements upsets pharma

The US House of Representatives has cleared a controversial measure that, if signed into law, would ban "pay for delay" settlements between brand-name pharmaceutical companies and their generic competitors aimed at delaying the entry of generic medicines onto the market.